About Allovir (ALVR)
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to r... Read more
- USD0.76
- USD0.82
- USD0.76
- USD6.12
- 1.40%
- --
- 798.00
- 629.48k
- 86M
- 0.62
- -80.20%
Stock News
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
